ADVISORY, Oct. 21, 2014 (GLOBE NEWSWIRE) -- --
DBV Technologies (Nasdaq: DBVT), a clinical-stage specialty biopharmaceutical company, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) which will occur today, October 22.
Headquartered in Bagneux, France, DBV Technologies is focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®. The company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. DBV Technologies is focusing on severe food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies was incorporated in 2002.
In honor of the occasion, Dr. Pierre-Henri Benhamou, Co-founder, Chairman and Chief Executive Officer will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, October 22, 2014 – 9:15 a.m. to 9:30 a.m. ET
DBV Technologies Contacts:
Chief Financial Officer
+33(0)1 55 42 78 78
VP Finance, US Investor Relations & Strategy
Director, Corporate Communication & Business Development
+33(0)1 55 42 78 78
The Trout Group
U.S. Investor Relations
Rooney & Associates
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit Tumblr Page:
A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About DBV Technologies (Nasdaq:DBVT):
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure.
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.